Date: 2012-06-05
Type of information: Grant
Company: Exonhit (France)
Investors: OSEO (France)
Amount: € 1.93 million
Funding type: grants and redeemable advances
Planned used: Exonhit will use these funds to study tumor transcriptomic profiles on the basis of its proprietary Genome Wide SpliceArrayTM (GWSA) technology, and to apply its capabilities in diagnostic test development to translate these profiles into a companion diagnostic.
Others: Exonhit has been granted € 1,928,000 by OSEO, as part of its involvement in a consortium led by ERYTECH Pharma and funded under the program for "Strategic Industrial Innovation". € 1,126,000 were paid to Exonhit at the inception of the project during the first semester of 2012.
Headed by project leader ERYTECH Pharma, the consortium includes Exonhit, InGen BioSciences, AP-HP (Paris Public Hospitals), Inserm (National Institute for medical research), and Paris-Diderot University. It aims at developing innovative therapies for the enzymatic treatment of chemo- or radioresistant cancers, and tools enabling personalized care of patients. This project, endorsed by the Competitiveness Cluster Lyonbiopôle, will last 8 years. The total amount awarded to the consortium amounts to approximately €10.7 million.
Exonhit was selected to participate in both phases of the project by using its proprietary Genome Wide SpliceArrayTM (GWSA) technology, to study tumor transcriptomic profiles in the initial phase, followed by the use of its capabilities in diagnostic test development to translate these profiles into a companion diagnostic.
Exonhit will be responsible for:
1) the identification of biomarkers of susceptibility to therapeutic response in the context of reducing the risks associated with the development of treatments, and
2) the development of an enzymatic therapy companion diagnostic that will identify responders, thus improving personalized care.
Therapeutic area: Cancer - Oncology
